AbbVie’s tavapadon, an investigational oral once-daily dopamine D1/D5 partial agonist, is nearing a potential regulatory submission, bolstered by new post-hoc…
Read More

AbbVie’s tavapadon, an investigational oral once-daily dopamine D1/D5 partial agonist, is nearing a potential regulatory submission, bolstered by new post-hoc…
Read More
Enanta Pharmaceuticals is strategically positioned to capture a significant share of the largely undeveloped market for respiratory syncytial virus (RSV)…
Read More
The landscape of obesity treatment, a market projected to reach a staggering $1 trillion, is undergoing a profound transformation. While…
Read More
MSD (Merck & Co) has achieved a significant milestone in the fight against Human Immunodeficiency Virus (HIV) with the U.S.…
Read More
The global pharmaceutical market for obesity treatments is poised for a dramatic transformation, with a burgeoning segment of non-Glucagon-like peptide-1…
Read More
The burgeoning market for obesity treatments, propelled recently by the widespread adoption of GLP-1 receptor agonists, stands at a critical…
Read More
The burgeoning market for obesity treatments, now valued at an astonishing $1 trillion, stands at a pivotal juncture. While GLP-1…
Read More
The global market for head and neck squamous cell carcinoma (HNSCC) therapeutics is poised for significant expansion, with projections indicating…
Read More
Combining the targeted precision of monoclonal antibodies with the potent destructive power of cytotoxic payloads, Antibody-Drug Conjugates (ADCs) represent a…
Read More
The landscape of plaque psoriasis treatment is on the cusp of a significant shift with the U.S. Food and Drug…
Read More